Radiofrequency ablation for treatment of hypersplenism: A feasible therapeutic option

Guilherme Lopes P Martins, Joao Paulo G Bernardes, Marcello S Rovella, Raphael G Andrade, Publio Cesar C Viana, Paulo Herman, Giovanni Guido Cerri, Marcos Roberto Menezes

Abstract

We present a case of a patient with hypersplenism secondary to portal hypertension due to hepatosplenic schistosomiasis, which was accompanied by severe and refractory thrombocytopenia. We performed spleen ablation and measured the total spleen and ablated volumes with contrast-enhanced computed tomography and volumetry. No major complications occurred, thrombocytopenia was resolved, and platelet levels remained stable, which allowed for early treatment of the patient’s underlying disease. Previous work has shown that splenic radiofrequency ablation is an attractive alternative treatment for hypersplenism induced by liver cirrhosis. We aimed to contribute to the currently sparse literature evaluating the role of radiofrequency ablation (RFA) in the management of hypersplenism. We conclude that splenic RFA appears to be a viable and promising option for the treatment of hypersplenism.

Key words: Portal hypertension; Thrombocytopenia; Hypersplenism; Percutaneous radiofrequency ablation; Splenic ablation

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

_Schistosomiasis mansoni_, a chronic parasitic disease, is the most prevalent tropical liver disease in northeastern Brazil. Approximately 200 million individuals are affected by _Schistosoma mansoni_ (S. mansoni) worldwide, with 600 million infected to the infection. Approximately 5%-7% of patients infected by _S. mansoni_ progress to hepatosplenic schistosomiasis, which is the most severe form of the disease. These patients exhibit perportal fibrosis, portal hypertension, splenomegaly and cytopenia and have a risk of developing upper digestive tract bleeding[7-9].

Hypersplenism is a consequence of massive splenomegaly and commonly occurs in chronic liver diseases. In schistosomiasis, hypersplenism results from hyperplasia of the reticuloendothelial system and the subsequent venous congestion caused by portal hypertension. Studies have reported a correlation between increased splenic size and drops in blood cell count, mainly platelets. These findings depend on the severity of portal hypertension, as some studies have shown that thrombocytopenia is more common in hepatosplenic schistosomiasis, especially after episodes of digestive tract bleeding[7-9].

There are many treatment modalities for hypersplenism secondary to portal hypertension, including splenectomy and embolization of the splenic artery[10-12]. These treatments are effective in the prevention of bleeding and in the correction of thrombocytopenia, but they are associated with high morbidity[13,14], as portal vein thrombosis, pain, splenic abscess and even rupture can occur in cases of splenic embolization[14-17].

Splenectomy remains a popular choice for the treatment of patients with spleen diseases and hypersplenism. However, it has been shown that the preservation of at least 25% of the splenic parenchyma ensures the maintenance of organ function in the short and long term[18], thereby avoiding post-splenectomy infection[18,20] and reducing immunologic induction of thrombocytopenia[21]. Therefore, preservation of splenic function by less invasive therapies has gained a place in the current therapeutic context.

Thermal ablation represents an important technological advance, with radiofrequency ablation (RFA) being the most commonly used technique. RFA is a minimally invasive and well-accepted method used mainly in the treatment of solid tumors of various organs such as the kidneys, liver and lungs[22,23]. The literature on splenic RFA is sparse, and the main indication is local control of neoplasms, but this technique has also been used for the treatment of infected hydatid cysts, hypersplenism and hemostasis in trauma[13,22-27].

There are no standardized criteria for splenic RFA in patients with hypersplenism. In some studies, this minimally invasive treatment has been shown to be safe and less expensive than conventional therapies; however, more studies are needed to determine the effectiveness of splenic ablation in patients with this condition[15,18,23,28].

Here, we report a case of a patient with hypersplenism and severe thrombocytopenia secondary to schistosomiasis. To receive systemic chemotherapy, splenic RFA is indicated to treat the resulting thrombocytopenia, as every other therapeutic possibility was contraindicated.

CASE REPORT

A 60-year-old male patient with a diagnosis of hepatosplenic schistosomiasis since 1989 presented with portal hypertension, esophageal varices, persistent thrombocytopenia secondary to hypersplenism (between 37000 and 44000/mm³ platelets), and chest pain. A CT scan showed a mass in the mediastinum, and a biopsy led to the diagnosis of a moderately differentiated thymoma (type B3) (Figure 1). The patient also suffered from comorbidities (i.e., severe hypertension, dyslipidemia and diabetes), which were difficult to control. Chemotherapy was proposed to treat the patient’s thymoma; however, it was necessary to improve the thrombocytopenia before the treatment could commence.

Because of the high morbidity associated with splenectomy, splenic artery embolization was the first choice of treatment. However, the CT scan showed a critical stenosis of the celiac trunk, which precluded the use of this procedure (Figure 1). Therefore, once informed consent was obtained from the patient, we chose to perform splenic RFA, which we present here as an alternative treatment option for hypersplenism.

The patient was positioned obliquely, with his right side down on the CT table, and the ablation was conducted under general anesthesia with prophylactic antibiotics. For treatment planning, a non-enhanced CT scan (Philips Brilliance 40) was acquired. Images in axial, sagittal, and coronal planes were reconstructed.
and an experienced interventional radiologist chose the optimal puncture approaches and sequences. A single 3 cm internally cooled electrode (Cool-Tip; Covidien, Mansfield, Massachusetts) was percutaneously introduced into the spleen under CT fluoroscopic guidance and was repositioned multiple times to cover most of the parenchyma (mainly the middle and lower thirds, avoiding central and subcapsular regions) to ablation of more than 50% of the splenic parenchyma (Figure 2). Using an impedance control algorithm, RF energy was applied during internal cooling of the electrode, with a maximum power of 150 W for 6-12 min in each punctured site, for a total procedure time of 4 h.

A contrast-enhanced CT scan confirmed that the ablated area was concentrated to the middle and lower thirds of the spleen and represented approximately 70% of the spleen parenchyma (initial volume of 1296.2 cc, leaving only 359.5 cc) (Figure 3).

After the procedure, the patient developed mild hematuria associated with acute renal failure, which was characterized by moderate elevation of blood urea and creatinine. This complication was completely resolved after ten days of hospitalization, without the need for dialysis.

The platelet count increased to 225000/mm³ three weeks after the procedure. A post-procedure leukocytosis, which was most likely secondary to systemic inflammatory response syndrome (commonly observed in patients undergoing ablation of large volumes of tissue), also completely resolved after one week. Chemotherapy was started one month after ablation.

**DISCUSSION**

In the context of liver disease and portal hypertension, where an enlarged spleen often leads to thrombocytopenia, the need for chemotherapy can present special problems. Cytotoxic chemotherapeutic regimens often induce bone marrow suppression, which can also result in thrombocytopenia. When
this condition occurs, many patients must stop their treatment because serious and potentially lethal side effects may occur due to severe leucopenia and thrombocytopenia.

Patients with thrombocytopenia who are offered a splenectomy must present good functional status, preferably with thrombocytopenia as the only factor limiting surgical treatment. By using these stringent preoperative criteria prior to splenectomy, perioperative morbidity and mortality can be minimized.

Splenectomy can eliminate hypersplenism, but morbidity ranges from 9.6% to 26.6%, when considering both laparoscopic and open approaches. Perioperative complications include bleeding, atelectasis, portal vein thrombosis (range: 1.6% to 11%) and subphrenic abscess formation. The major long-term risk after splenectomy is overwhelming sepsis (up to a 30-fold increase when compared to the normal population). Other complications are thrombophilia, pulmonary hypertension, and death.

Patients who are not good candidates for splenectomy may opt for splenic artery embolization, as this treatment can also potentially reverse hypersplenism-induced thrombocytopenia. Embolization is considered to be the second line of treatment because it can lead to significant postoperative pain and splenic abscesses. In a large series, Zhu et al. found that in partial splenic embolization, the splenic infarction rate should be limited to 50%-70% to ensure long-term efficacy in alleviating hypersplenism and thrombocytopenia, as assessed by good outcome at the 5-year follow-up. In their series, the most common complications were post-embolization syndrome, followed by transient pleural effusion and/or ascites, as well as small left-sided atelectasis.

Portal vein thrombosis, severe bacterial peritonitis, and splenic abscess resulting in death have also been reported.

Because of severe comorbidities, high surgical risk, significant stenosis of the celiac trunk, and the need to prevent splenic embolization (first and second lines of treatment), our patient underwent splenic ablation as a last resort to revert thrombocytopenia.

There are no standardized selection criteria for the use of splenic RFA to treat hypersplenism; therefore, the indication of this procedure is individualized and case-based. In several published studies, the indication was based on the individual authors’ experience, which included severe disease with persistent thrombocytopenia (between 15000 and 100000 platelets), persistent leucopenia, splenic volumes of less than 1500 mL, absence of esophageal varices and/or previous treatment of the varices, absence of portal vein or hepatic veins thrombosis, and prothrombin time less than 22 s.

The RFA ablation can be performed percutaneously, laparoscopically or with open surgery. The percutaneous approach is preferred because it is minimally invasive, results in a shorter recovery time, and allows for good visualization of the entire needle and the insertion site. Ultrasound or computed tomography may be used for guidance, and multiple regions of the spleen can be ablated or multiple needles can be used simultaneously, keeping in mind that the needle should be positioned at a certain distance from the splenic capsule and the vessels of the hilum. Although radiofrequency electrodes can be inserted into any portion of the spleen, the middle and lower thirds may be the best sites to avoid thermal damage to surrounding organs and reduce postoperative complications (particularly pleural effusion).

Because of its superior resolution, we chose to use a percutaneous CT-guided approach, and we concentrated the ablation zones to the middle and lower thirds of the spleen, avoiding the central and upper portions, as previously described in the literature.

There is still no consensus regarding how much parenchyma should be ablated to ensure the resolution of thrombocytopenia while also avoiding complications. It has been shown that splenic ablation can lead to good outcomes in the short-term; however, the long-term results depend on the volume of ablated parenchyma. Liang et al. divided patients into 3 groups based on the volume of ablation performed (less than 20%, 20%-40% and over 40%) and observed that larger ablation volumes (> 40%) yielded better clinical results, which was similar to the findings by Liu et al., who observed positive results after ablation of ≥ 40% of the spleen. Moreover, Feng et al. reported that patients with more than 50% of ablated parenchyma showed positive results after treatment.
better clinical control than patients with smaller ablated volumes and that the results were even better when the ablation volume was greater than 70%. After 5 years of follow-up, these authors concluded that the ablation volume should ideally be between 50% and 70%. In the present case, resolution of thrombocytopenia in the short and medium terms was essential for the systemic treatment indicated for the patient. After ablation, the platelet count reached 225000 mm³ in 3 wk and remained between 80000 and 120000/mm³ at the 24-mo follow-up (Figure 4).

The procedure lasted 4 h, and only one single radiofrequency probe was used. Therefore, to achieve adequate ablation volumes with single electrodes, multiple overlapping sessions are required [40,41], in clinical practice, repositioning electrodes is time consuming and even technically challenging. Several types of electrodes and even different techniques have been developed to overcome this limitation and achieve greater ablation zones, including clustered and multipolar electrodes [42,43], monopolar radiofrequency ablation with a multiple-electrode switching system [44,45] and even the use of microwave ablation [42,43]. Some studies have demonstrated that all of these techniques are promising and safe, sometimes allowing more energy delivery, with the advantage of being more efficient in creating a larger and confluent coagulation zone within a clinically acceptable and lower time frame than with conventional consecutive radiofrequency ablation, but with an increased cost.

The patient developed mild hematuria associated with acute renal failure after the procedure, which was characterized by moderate elevation of blood urea and creatinine and change in urine color. A literature search revealed that RFA can induce hemolysis in the experimental setting [47], which might be due to thermal injury of erythrocytes, leading to release of hemoglobin into the circulating blood [48], once blood hemolysis occurs when warmed up to 50 ℃ [49]. In addition, the procedure had an overall duration of 4 h, and patient positioning and prolonged immobilization are normally associated with rhabdomyolysis in surgical patients; unfortunately, no serum markers were measured in this case [50]. Nevertheless, there are no proven factors that can predict acute renal failure in cases such as this, but patients who require larger ablation volumes and longer operating times, and those with low-flow state should be closely monitored for this complication [50]. In conclusion, we believe that the most likely cause of transient acute renal failure in our case was hemolysis from prolonged and large volume radiofrequency ablation and that measures such as intravenous hydration and alkalization of urine should be adopted to avoid it when indicated [50].

The most common complications described in the literature associated with splenic RFA are transient low-grade fever, symptomatic pleural effusion (some patients required thoracentesis) and mild abdominal and left shoulder pain [15,25,26,39]. Less common complications include mild transient hemoglobinuria and mild hematuria [25,39], skin bruises [25], portal vein thrombosis [25] and intra-abdominal hemorrhage [39]. Splenic rupture, refractory ascites, thermal injury to adjacent organs (including stomach, pancreas and colon), liver dysfunction and acute pancreatitis are other life-threatening complications that could potentially occur but have not been reported in the literature.

In summary, splenic ablation was the last-resort chosen to resolve this patient’s thrombocytopenia. Despite the occurrence of a major complication that was clinically monitored and no further observed consequences, in this case percutaneous splenic RFA was successful in managing hypersplenism thrombocytopenia in a safe, effective, and minimally invasive manner; which makes it a treatment option in patients who are not candidates for surgery or an endovascular intervention. Nevertheless, more studies are needed to determine the best technique for each case, taking into consideration the success and complication rates associated with each procedure.

Figure 4  Graph above shows good recovery of platelet levels in a short period of time following the procedure, maintaining adequate levels during follow-up, and allowing chemotherapy to be conducted.

Platelets/mm³

Pre-treatment  60 d  90 d  180 d  1 yr  1.5 yr  2 yr
 Begin of chemotherapy
 Spleen ablation

Martins GLP et al. RFA for hypersplenism

Platelets/mm³

Pre-treatment  60 d  90 d  180 d  1 yr  1.5 yr  2 yr
 Begin of chemotherapy
 Spleen ablation

Platelets/mm³

Pre-treatment  60 d  90 d  180 d  1 yr  1.5 yr  2 yr
 Begin of chemotherapy
 Spleen ablation

Platelets/mm³

Pre-treatment  60 d  90 d  180 d  1 yr  1.5 yr  2 yr
 Begin of chemotherapy
 Spleen ablation

Platelets/mm³

Pre-treatment  60 d  90 d  180 d  1 yr  1.5 yr  2 yr
 Begin of chemotherapy
 Spleen ablation
COMMENTS

Case characteristics
This is a 60-year-old male patient with a diagnosis of hepatosplenic schistosomiasis and persistent thrombocytopenia, who presented with a moderately differentiated thymoma.

Clinical diagnosis
Dullness to percussion and pain on palpation of the left hypochondrium, associated with an increased spleen.

Differential diagnosis
Hypersplenism, abdominal tumor in the left hypochondrium.

Laboratory diagnosis
WBC 1.81 k/uL, HGB 14.2 gm/dL; Platelets: between 37000 and 44000/mm³; metabolic panel and liver function test were within normal limits.

Imaging diagnosis
Thoracic CT scan showed an anterior mediastinal mass measuring approximately 9.2 cm x 7.3 cm. Abdominal imaging showed signs of chronic liver disease associated with portal hypertension and an estimated spleen volume of 1296.2 cc.

Pathological diagnosis
Biopsy revealed a moderately differentiated thymoma (type B3). Hypersplenism had no pathological diagnosis.

Treatment
The patient was treated for hypersplenism with radiofrequency ablation (initial volume of 1296.2 cc, leaving only 359.5 cc) to revert thrombocytopenia.

Related reports
Chemotherapy was proposed to treat the patient’s thymoma; however, it was necessary to revert thrombocytopenia to initiate the treatment, as cytotoxic chemotherapeutic regimens often induce bone marrow suppression, and serious and potentially lethal side effects may occur due to severe leucopenia and thrombocytopenia.

Term explanation
Thermal ablation showed great progress with new technological advances, and radiofrequency ablation (RFA) is the most used among our group and has attracted much attention because it is minimally invasive and well accepted. RFA is based on the principle of coagulative necrosis of tumors at temperatures above 50 °C, generating a tissue dehydration and protein denaturation.

Experiences and lessons
This case report presents radiofrequency ablation as an alternative treatment for hypersplenism, proving to be not only a safe procedure, but also effective in controlling thrombocytopenia, which makes it a viable option especially when surgery or an endovascular intervention are contraindicated.

Peer-review
The authors have described one case of thrombocytopenia secondary to hypersplenism that needed to be reverted to initiate chemotherapy for the patient. The article highlights RFA as an alternative option for treating hypersplenism and provides some technical aspects and clinical outcome after spleen radiofrequency ablation.

REFERENCES

1. Leite LA, Domingues AL, Lopes EP, Ferreira RD, Pimenta AD Filho, da Fonseca CS, dos Santos BS, Lima VL. Relationship between splenomegaly and hematologic findings in patients with hepatosplenic schistosomiasis. Rev Bras Hematol Hemoter 2013; 35: 332-336 [PMID: 24255616 DOI: 10.5581/1516-8484.20130098]
2. Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP. Schistosomiasis. N Engl J Med 2002; 346: 1212-1220 [PMID: 11961151 DOI: 10.1056/NEJMra012396]
3. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106-1118 [PMID: 16997665 DOI: 10.1016/ S0140-6736(06)69440-3]
4. Coutinho EM, Abath FG, Barbosa CS, Domingues AL, Melo MC, Montenegro SM, Lucena MA, Romani SA, Souza WV, Coutinho AD. Factors involved in Schistosoma mansoni infection in rural areas of northeast Brazil. Mem Inst Oswaldo Cruz 1997; 92: 707-715 [PMID: 9566243]
5. Madass FF, Hernandez P, Pugliese V, de Caira R, Saad WA, Casconello I, D’Albuquerque L. Long-term results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in schistosomal portal hypertension. World J Surg 2010; 34: 2682-2688 [PMID: 20645097 DOI: 10.1007/s00268-010-0717-8]
6. Ferraz AA, de Albuquerque PC, Lopes EP, de Araújo JG, Carvalho AH, Ferraz EM. The influence of peripetal (pipetam) fibrosis on long term results of surgical treatment for schistosomotic portal hypertension. Arq Gastroenterol 2003; 40: 4-10 [PMID: 14534657]
7. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 1009-1031 [PMID: 11193552 DOI: 10.1016/S1208-863X(00)00144-1]
8. Bosch J, Abraldes JG, Benitez J, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008; 28: 3-25 [PMID: 18293274 DOI: 10.1055/s-2008-1040318]
9. Correia MC, Domingues AL, Lacera RD, Santos EM, Machado CG, Hora V, Neves MA, Brito A, Coelho MR, Silva JL. Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. Trans R Soc Trop Med Hyg 2009; 103: 1053-1058 [PMID: 19118853 DOI: 10.1016/j.trm.2008.11.017]
10. Tripathi D, Therapondos G, Jackson E, Redhead DN, Hayes PC. The role of the transjugular intrahepatic portosystemic shunt stent (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. Gut 2002; 51: 270-274 [PMID: 12117893]
11. Kokenis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the English language literature. J Vasc Interv Radiol 2007; 18: 463-481 [PMID: 17446537 DOI: 10.1016/j.jvir.2006.12.734]
12. Henderson JM, Boyer TD, Kutter MH, Galloway JR, Rikkers LF, Jeffers LJ, Abu-Elmagd K, Connor J. Distal splenorenal shunt versus transjugular intrahepatic portal systemic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130: 1643-1651 [PMID: 16697728 DOI: 10.1053/j.gastro.2006.02.006]
13. Enne M, Facchini Mexia LF, Balbi E, Martinho JM. Transjugular intrahepatic portosystemic shunt versus H-graff portalavval shunt in the management of bleeding varices: a cost-benefit analysis. Ann Surg 2006; 243: 139-40; author reply 140 [PMID: 16371752]
14. Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br J Surg 2008; 95: 744-750 [PMID: 18412294 DOI: 10.1002/bjs.6081]
15. Feng K, Ma K, Liu Q, Wu Q, Dong J, Bie P. Randomized clinical trial of splenic radiofrequency ablation versus splenectomy for severe hypersplenism. Br J Surg 2011; 98: 354-361 [PMID: 21254007 DOI: 10.1002/bjs.7367]
16. Matsuoka T, Yamamoto A, Okuma T, Oyama Y, Nakamura K, Inoue Y. CT-guided percutaneous radiofrequency ablation of spleen: a preliminary study. AJR Am J Roentgenol 2007; 188: 1044-1046 [PMID: 17377043 DOI: 10.2214/AJR.06.0641]
17. Eguchi A, Hashizume M, Kitano S, Tanoue K, Wada H, Sugimachi K. High rate of portal thrombosis after splenectomy in patients with esophageal varices and idiopathic portal hypertension. Arch Surg 1991; 126: 752-755 [PMID: 2039363]
18. Karadayi K, Turan M, Sen M. A new technique for partial splenectomy with radiofrequency technology. Surg Laparosc Endosc Percutan Tech 2011; 21: 359-361 [PMID: 22002274 DOI: 10.1097/01.013e.0000428365]
19. Dwivedi MK, Pai RK, Dwawala L, Nag P. Efficacy of partial splenectomy in the management of hypersplenism. Indian J Radiol Imaging 2002; 12: 371-374
20. Amin MA, e-Gindy MM, Dawoud IE, Shoma A, Negm AM, Amer TA. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg 2009; 33: 1702-1710 [PMID: 19513783 DOI: 10.1007/s00266-009-0955-2]
21. Nozuchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995; 22:
**Partial splenic embolization:**

- **FS.** Partial splenic embolization: 12-month hematological effects and complications. *Diag Interv Radiol* 2012; 18: 397-402 [PMID: 22322881 DOI: 10.4261/1305-3825]

- **Donahue TR,** Kazanjian KK, Isacoff WH, Reber HA, Hines OJ. Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer. *J Gastrointest Surg* 2010; 14: 1012-1018 [PMID: 20309646 DOI: 10.1007/s11605-010-1187-x]

- **Zhu K,** Meng X, Qian J, Huang M, Li Z, Guan S, Jiang Z, Shan H. Partial splenectomy for hypersplenism in patients with liver cirrhosis: a pilot study. *Dig Liver Dis* 2009; 41: 411-416 [PMID: 19070555 DOI: 10.1016/j.dld.2008.10.005]

- **Winslow ER,** Brunt LM. Perioperative outcomes of laparoscopic versus open splenectomy: a meta-analysis with an emphasis on complications. *Surgery* 2003; 134: 647-653; discussion 654-655 [PMID: 14605626 DOI: 10.1016/S0039-6010(03)00399-5]

- **Watanabe Y,** Horuchi A, Yoshida M, Yamamoto Y, Sugishita H, Kumagi T, Hissya Y, Kawakami K. Effectiveness of laparoscopic splenectomy in patients with hypersplenism. *World J Surg* 2007; 31: 549-555 [PMID: 17308852 DOI: 10.1007/s00268-006-0504-8]

- **Kojouri K,** Vesely SK, Terrell DK, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. *Blood* 2004; 104: 2623-2634 [PMID: 15217831 DOI: 10.1182/blood-2004-03-1168]

- **Taher AT,** Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Salind MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. *Blood* 2010; 115: 1886-1892 [PMID: 20032507 DOI: 10.1182/blood-2009-09-243154]

- **Wang HY,** Shih SC, Lin SC, Chang WS, Wang TE, Lin FJ, Yang FS. Partial splenic embolization: 12-month hematological effects and complications. *Hepatogastroenterology* 2008; 55: 1838-1842 [PMID: 19102404]

- **Yoshida H,** Mamada Y, Tanii N, Tajiri T. Partial splenic embolization. *Hepatol Res* 2008; 38: 225-233 [PMID: 18034810 DOI: 10.1111/j.1872-034X.2007.00302.x]

- **N’Kontcho G,** Seror O, Bourcier V, Mohand D, Avajov Y, Castera L, Grando-Lemaire V, Ganne-Carrie N, Sellier N, Trinchet JC, Beaugrand M. Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. *Eur J Gastroenterol Hepatol* 2005; 17: 179-184 [PMID: 15674095]

- **Shiraki K,** Shiraki Y, Inoue H, Sugimoto K, Ohmori S, Murata K, Takase K, Nakano T. Complications of partial splenic embolization in cirrhotic patients. *Dig Dis Sci* 2002; 47: 388-391 [PMID: 11855556 DOI: 10.1021/A1013786509418]

- **Liang P,** Gao Y, Zhang H, Yu X, Wang Y, Duan Y, Shi W. Microwave embolization in the spleen for treatment of secondary hypersplenism: a preliminary study. *AJR Am J Roentgenol* 2011; 196: 692-696 [PMID: 21343515 DOI: 10.2214/AJR.10.4193]

- **Chen MH,** Yang W, Yan K, Zou MW, Solbiati L, Liu JB, Dai Y. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients—mathematic model, overlapping mode, and electrode placement process. *Radiology* 2004; 232: 260-271 [PMID: 15166323 DOI: 10.1148/radiol.2321030821]

- **Dodd GD,** Frank MS, Aribandi M, Chopra S, Chintapani KL. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. *AJR Am J Roentgenol* 2001; 177: 777-782 [PMID: 11566672 DOI: 10.2214/ajr.177.4.177077]

- **Horigome H,** Nomura T, Nakao H, Fujino N, Murasaki G, Kanematsu T, Joh T, Ohara H, Ioh M. Percutaneous radio-frequency ablation therapy using a clustered electrode for malignant liver tumors. *J Clin Gastroenterol* 2013; 47: 418-422 [PMID: 13193141]

- **Miao Y,** Ni Y, Yu J, Zhang H, Baer A, Marchal G. An ex vivo study on radiofrequency tissue ablation: increased lesion size by using an “expandable-wet” electrode. *Eur Radiol* 2001; 11: 1841-1847 [PMID: 11511912 DOI: 10.1007/s003300100891]

- **Lee JM,** Han JK, Kim HC, Kim SH, Kim KW, Joo SM, Choi BI. Multiple-electrode radiofrequency ablation of in vivo porcine liver: comparative studies of consecutive monopolar, switching monopolar versus multipolar modes. *Invest Radiol* 2007; 42: 676-683 [PMID: 17984764 DOI: 10.1097/RLI.0b013e318066e1ad]

- **Laescke PF,** Sampson LA, Haenmuerth D, Brace CL, Fine JP, Frey TM, Winter TC, Lee FT. Multiple-electrode radiofrequency ablation creates confluent areas of necrosis: in vivo porcine liver results. *Radiology* 2006; 241: 116-124 [PMID: 16928978 DOI: 10.1148/ radiol.241015127]

- **Gao Y,** Wang Y, Duan Y, Li C, Sun Y, Zhang D, Lu T, Liang P. 915MHz microwave ablation with high output power in in vivo porcine spleens. *Eur Radiol* 2010; 15: 87-90 [PMID: 19349134 DOI: 10.1007/s00330-009-0509]

- **Tsui SL,** Lee AK, Lui SK, Poon RT, Fan ST. Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. *Hepatogastroenterology* 2003; 50: 526-529 [PMID: 12749264]

- **Li H,** Li B, Wei Y, Liu F. Hemolysis as a complication of radiofrequency ablation for hepatocellular carcinoma must be paid more attention. *Dig Dis Sci* 2011; 56: 3391-3392 [PMID: 21567919 DOI: 10.1007/s10620-011-1737-4]

- **Keltner JR,** Donegan E, Hynson JM, Shapiro WA. Acute renal failure after radiofrequency liver ablation of metastatic carcinoid tumor. *Anesth Analg* 2001; 93: 587-590 [PMID: 11524322]

- **Rodriguez J,** Tellieglo G, Sipeterin A, Berber E. Myoglobinuria after laparoscopic radiofrequency ablation of liver tumors. *J Gastrointest Surg* 2010; 14: 664-667 [PMID: 20033345 DOI: 10.1007/s11605-009-1118-a]
